Thymogen — the Glu-Trp dipeptide immunomodulator, explained
Thymogen (also spelled Thymogenum; chemical name L-γ-glutamyl-L-tryptophan, or Glu-Trp) is a synthetic dipeptide developed in the 1980s at the St. Petersburg Institute of Bioregulation and Gerontology by the research program led by Vladimir Khavinson. It is part of the 'cytomedine' class of short regulatory peptides that emerged from the Khavinson program — a line of research focused on 2-4 residue peptides with proposed tissue-specific immunomodulatory effects. Thymogen is one of the more-studied compounds in this family, particularly in Russian-language immunology literature. This primer covers the molecule, the Khavinson research program context, the published literature, and what researchers should know about the provenance of the evidence base.
The molecule. Thymogen is the dipeptide glutamyl-tryptophan with a γ-linkage (L-γ-glutamyl-L-tryptophan). Molecular formula: C16H19N3O5. Molecular weight: 333.34 Da. The γ-glutamyl linkage (connecting the side-chain carboxyl of glutamate to the α-amino of tryptophan, rather than the more common α-peptide bond between backbone carboxyl and amino groups) is unusual in pharmaceutical peptides and shifts the molecule's structural and metabolic properties relative to the α-linked Glu-Trp. This is a small, relatively stable, and unusually simple molecule by peptide-research standards — which is both a feature (cheap to synthesize, stable to store) and a question (how does such a small molecule achieve tissue-specific effects at the cellular level).
The Khavinson cytomedine program. The research program that produced thymogen is distinctive in the global peptide-research landscape. Vladimir Khavinson and colleagues published several hundred papers from the 1980s through the 2010s on 2-4 residue peptides with proposed organ-specific regulatory effects — thymogen (thymic), thymalin (thymic complex), epitalon/epithalon (pineal), cortexin (cerebral cortex), pinealon (pineal), and others. The program's core hypothesis is that short 'regulatory peptides' can act as transcriptional modulators in a tissue-specific manner, with particular affinity for the tissue of origin. Most of this literature is Russian-language or Russian-first-authored, published in journals with limited Western readership (Bulletin of Experimental Biology and Medicine; Advances in Gerontology; Neuroendocrinology Letters). Independent replication from non-Khavinson groups is thinner than the absolute citation count suggests. This does not invalidate the research base — but researchers should weight it with awareness of the provenance.
Published literature — primary sources. The foundational paper on synthetic thymus peptides including thymogen is Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19(9-10):501-505 (doi: 10.1016/s0192-0561(97)00058-1). The broader Khavinson-program context is captured in Khavinson VK, Malinin VV. Gerontological aspects of genome peptide regulation. Basel: Karger; 2005 (ISBN: 3-8055-7904-5), a monograph summarizing the program's mechanistic claims. A useful Western-indexed overview of the short-peptide program is Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149 (doi: 10.1007/s10522-009-9249-8). Beyond these program-level sources, specific thymogen papers are predominantly in Russian-language journals indexed in RSCI but not in PubMed-central.
Proposed mechanisms. The Khavinson program's central mechanistic claim for thymogen is that it acts as a T-lymphocyte differentiation modulator, shifting immature thymocytes toward mature T-cell phenotypes and rebalancing T-helper / T-suppressor ratios in immunosenescent or immune-dysregulated states. At the molecular level the program has proposed (a) direct effects on the thymic microenvironment, (b) modulation of cytokine production by thymic epithelial cells, and (c) — in later Khavinson papers — direct binding to specific DNA sequences and transcriptional regulation. The DNA-binding mechanism is the most speculative and least-independently-replicated; the T-lymphocyte maturation effect is the most-documented observation in the available literature.
Research applications. Thymogen has been studied in (1) immune-function research in aged rodents and humans, particularly in the context of immunosenescence — age-related declines in T-cell repertoire and function; (2) recovery from immunosuppression — research in post-chemotherapy, post-radiation, and post-surgical-stress settings; (3) antiviral-response research, where thymogen has been positioned as an immune-modulator rather than a direct antiviral; (4) thymic-function research more broadly — alongside other Khavinson-program compounds (thymalin, splenopentin). The evidence base is primarily Russian clinical and preclinical; Western independent replication is limited.
Where the evidence is weaker than citation counts suggest. Thymogen's research literature has the following characteristics researchers should be aware of: (1) most studies are small-N open-label or single-center; blinded randomized controlled trials are rare; (2) endpoints are often surrogate immunological markers (T-cell subset counts, cytokine ratios) rather than hard clinical outcomes; (3) most studies originate from the Khavinson program or groups directly collaborating with it, rather than independent replication; (4) the Russian clinical approval of thymogen in the 1990s-2000s did not go through the kind of regulatory review standard in FDA or EMA clinical-development pipelines. None of this means thymogen does nothing — but the strength of evidence is below what Western pharmacology research would require for novel immunomodulators.
Administration routes and dose ranges. Russian research protocols have used intramuscular, intranasal (as spray), and rectal-suppository formats. Injectable research doses are typically 100 μg per administration, daily for 3-10 days in cycled protocols. The cycled-dosing protocol is a hallmark of Khavinson-program compounds generally — a short course (5-10 days) followed by a rest period (weeks to months), repeated periodically. Vivaprime supplies thymogen at 10 mg/mL concentration (30 mg per 3 mL pen), a research-appropriate concentration for multi-site research-lab work. The 100 μg clinical dose translates to a small per-dose volume at this concentration.
Storage and handling. Thymogen is unusually stable compared to larger peptides due to its small size. Refrigerate 2-8 °C. Protect from light. Do not freeze. In-use stability is well-characterized in the Russian clinical formulations; prefilled-pen format adopts the 28-day convention for consistency with larger peptides in the catalog. The γ-glutamyl linkage is stable to standard aqueous handling at neutral pH.
What the COA should say. A batch-specific COA for thymogen should include (1) identity by HPLC-MS matching theoretical mass 333.34 Da — a small molecule by peptide standards, so MS identity is straightforward, (2) purity by reverse-phase HPLC ≥ 98%, (3) endotoxin by LAL in EU/mg, (4) optical rotation / chiral purity — because thymogen contains defined L-stereochemistry at both residues, D-isomer content should be specified. Solid-phase synthesis is the dominant production route; the γ-glutamyl linkage requires specific coupling chemistry distinguishing from routine α-peptide synthesis.
Research-use only. Vivaprime supplies thymogen as research reference material for qualified researchers engaged in in-vitro and research-context work. Thymogen has not been approved by the FDA or EMA for any therapeutic indication. It holds Russian regulatory approval for specific clinical indications, but that approval is not cross-recognized in US or EU research-compound regulations. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout. Related primers: [thymalin](/blog/thymalin-research-primer), [epithalon](/blog/epithalon-research-primer).